Burlington – October 12, 2026 -- Eighty-six percent of 21 heart failure patients at imminent risk of hospital admission were decongested at home without hospitalization using SQ Innovation's subcutaneous furosemide product Lasix ONYU, according to interim results from the investigator-sponsored Gator SCALES-WHF study.

Three patients were admitted within 30 days for additional treatment. The data were presented on October 11 at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026 in Phoenix, Arizona.